The U.S. Food and Drug Administration recently approved aducanumab, the first treatment that aims to slow the progression of Alzheimer’s disease. But approval of the drug has provoked mixed reactions from the scientific community.
Provincial governments are watching vaccination rates closely as pharmacies across the country provide more first and second doses thanks to increased supply.